Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
A Randomized, Double-blind, Placebo-controlled, Efficacy Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Patients With Atopic Dermatitis
Sponsor: Vanda Pharmaceuticals
Terminated
Business Decision
Other terminated trials from Vanda Pharmaceuticals
Other Atopic Dermatitis trials with similar outcome
Listed as NCT04140695, this PHASE3 trial focuses on Atopic Dermatitis and remains terminated or withdrawn. Sponsored by Vanda Pharmaceuticals, it has been updated 10 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Completed → Terminated
-
Jun 2022 — Jun 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — May 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vanda Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .